Oculis Holding AG (OCS) Times Interest Earned (2022 - 2026)
Oculis Holding AG (OCS) posted quarterly Times Interest Earned of $658.42 for Q1 2026, down 60.44% year-over-year from $1664.5 in Q1 2025, and up 14.88% quarter-over-quarter from $573.14 in Q4 2025.
Oculis Holding AG (OCS) Times Interest Earned (2022 - 2026) Analysis & Trends
Oculis Holding AG's Times Interest Earned history runs 5 years deep, the most recent figure standing at $658.42 for Q1 2026.
- In Q1 2026, Times Interest Earned fell 60.44% year-over-year to $658.42; the TTM figure through Mar 2026 stood at $168.31 (up 112.19% YoY), while the FY2025 annual figure was -$98.05, up 14.42% from the prior year.
- Times Interest Earned for Q1 2026 stood at $658.42, up from $573.14 in the prior quarter.
- The five-year high for Times Interest Earned was $1664.5 in Q1 2025, with the low at -$632.06 in Q2 2023.
- The 5-year median for Times Interest Earned is $0.55 (2025), against an average of $336.54.
- The sharpest annual moves came in 2023 and 2024: Times Interest Earned slumped 11491.84% in 2023, then soared 4429.21% in 2024.
- Oculis Holding AG's Times Interest Earned stood at -$8.5 in 2022, then slumped by 7333.64% to -$632.06 in 2023, then jumped by 310.06% to $1327.7 in 2024, then sank by 56.83% to $573.14 in 2025, then advanced by 14.88% to $658.42 in 2026.
- Business Quant data shows OCS's Times Interest Earned at $658.42 in Q1 2026, $573.14 in Q4 2025, and $0.04 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -30.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.07 |
| Mar 31, 2026 | 658.42 |
| Dec 31, 2025 | 573.14 |
| Sep 30, 2025 | 0.04 |
| Jun 30, 2025 | -113.49 |
| Mar 31, 2025 | 1,664.50 |
| Dec 31, 2024 | 1,327.69 |
| Sep 30, 2024 | 1.07 |
| Jun 30, 2024 | -258.45 |
| Mar 31, 2024 | 1,532.80 |
| Jun 30, 2023 | -632.06 |
| Mar 31, 2023 | -35.41 |
| Dec 31, 2022 | -8.50 |
| Sep 30, 2022 | -3.80 |
| Jun 30, 2022 | 5.55 |